Search results for "Cutaneous"

showing 10 items of 1022 documents

Characteristics of mucocutaneous vascular malformations drawn from a decade of a multidisciplinary committee experience.

2021

Vascular malformations (VM) are congenital, benign, and relatively frequent lesions. Scant data have been published about the epidemiology, clinical presentation, and treatment of VM from a dermatologist's perspective. The substantial differences between subtypes, broad range of specialists consulted and confusing nomenclature used over previous years may hamper a correct diagnosis. The main objective of this study is to describe VM epidemiology. As a secondary endpoint we evaluate clinical characteristics, clinical-radiological correlation and treatment approaches. We carried out an observational, descriptive, retrospective study. Cases presented to the multidisciplinary committee of our h…

medicine.medical_specialtyLymphatic Abnormalitiesbusiness.industryVascular MalformationsGeneral surgeryMedical recordmedicine.medical_treatmentMucocutaneous zoneRetrospective cohort studyDermatologyGeneral MedicineVeinsMultidisciplinary approachEpidemiologySclerotherapymedicineSclerotherapyHumansObservational studyCorPresentation (obstetrics)businessRetrospective Studies
researchProduct

Magnetic Resonance Assessment of Left Ventricular Ejection Fraction at Any Time Post-Infarction for Prediction of Subsequent Events in a Large Multic…

2021

Background Magnetic resonance imaging (MRI) is the most accurate imaging technique for left ventricular ejection fraction (LVEF) quantification, but as yet the prognostic value of LVEF assessment at any time after ST-segment elevation myocardial infarction (STEMI) for subsequent major adverse cardiac event (MACE) prediction is uncertain. Purpose To explore the prognostic impact of MRI-derived LVEF at any time post-STEMI to predict subsequent MACE (cardiovascular death or re-admission for acute heart failure). Study Type Prospective. Population One thousand thirteen STEMI patients were included in a multicenter registry. Field Strength/Sequence 1.5-T. Balanced steady-state free precession (c…

medicine.medical_specialtyMagnetic Resonance SpectroscopyPopulationContrast MediaMagnetic Resonance Imaging CineGadoliniumVentricular Function Left030218 nuclear medicine & medical imaging03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionPredictive Value of TestsInternal medicineMedicineHumansRadiology Nuclear Medicine and imagingMyocardial infarctionProspective StudiesRegistriescardiovascular diseasesStage (cooking)educationriskeducation.field_of_studyEjection fractionmedicine.diagnostic_testbusiness.industryIncidence (epidemiology)Magnetic resonance imagingStroke Volumeleft ventricular ejection fractionmedicine.diseasePrognosisMagnetic Resonance ImaginghumanitiesST-segment elevation myocardial infarctionHeart failureCardiologycardiovascular systemST Elevation Myocardial InfarctionprognosisbusinessMacecirculatory and respiratory physiology
researchProduct

Ultrasound-guided percutaneous treatment of calcific bursitis of the medial collateral ligament of the knee

2021

Calcific bursitis of the medial collateral ligament of the knee is an infrequent pathological condition. In 1988, Kerlan and Glousman identified the clinical features of medial collateral ligament bursitis. Pain and knee functions limitation are the clinical symptoms that are most frequently encountered during the reactive inflammatory process in the bursa, that characterizes the reabsorption phases of the calcific material. It is well documented in the literature that the maximum efficacy of ultrasound-guided percutaneous treatment, with significant reduction or disappearance of symptoms, occurs precisely in this phase. The case report presented in this study confirms the validity as a the…

medicine.medical_specialtyMedial collateral ligamentCase reportsPercutaneousbusiness.industryPhysical Therapy Sports Therapy and Rehabilitationmedicine.diseaseUltrasound guidedCalcificationCalcific bursitismedicineKneeOrthopedics and Sports MedicineRadiologyPhysiologicbusinessMedicina dello Sport
researchProduct

Effects of topical treatment with the raft modulator miltefosine and clobetasol in cutaneous mastocytosis: a randomized, double-blind, placebo-contro…

2009

Background Mastocytosis is characterized by the accumulation and activation of mast cells in different organs, most commonly the skin. Miltefosine, a raft modulator, has recently been shown to inhibit the activation of mast cells and to reduce mast cell-driven skin inflammatory responses. Objectives To study the safety and efficacy of topical miltefosine treatment of skin lesions in patients with mastocytosis. Methods Thirty-nine adult patients with mastocytosis with skin involvement were treated in a double-blind, placebo-controlled, parallel trial with topical miltefosine and clobetasol for 2 weeks. Treatment areas were analysed for changes in skin lesions and symptoms following mechanica…

medicine.medical_specialtyMiltefosinebusiness.industryCutaneous MastocytosisProvocation testPlacebo-controlled studyDermatologyMast cellDermatologylaw.inventionmedicine.anatomical_structurePharmacotherapyRandomized controlled trialDermislawMedicinebusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Safety and efficacy of MitraClip™ therapy in patients with severely impaired left ventricular ejection fraction: results from the German transcathete…

2017

Aims The aim of the present study was to assess the safety and efficacy of percutaneous mitral valve repair using the MitraClip™ device in patients with severely reduced systolic left ventricular (LV) function. Methods and results Among 777 MitraClip™ implantations included in the German mitral valve registry, we identified 256 patients suffering from severely reduced LV function [ejection fraction (EF) 50%) and 280 patients presenting with an EF 30–50% prior to MitraClip™ therapy. High procedural success rates, low periprocedural complication rates, and low residual mitral regurgitation grades at discharge were achieved throughout all groups. In-hospital mortality was low and comparable in…

medicine.medical_specialtyMitral regurgitationEjection fractionbusiness.industryMortality rateMitraClip030204 cardiovascular system & hematologymedicine.disease3. Good healthSurgery03 medical and health sciences0302 clinical medicinemedicine.anatomical_structureInternal medicineMitral valveHeart failuremedicineCardiology030212 general & internal medicineCardiology and Cardiovascular MedicinebusinessComplicationPercutaneous Mitral Valve RepairEuropean Journal of Heart Failure
researchProduct

Mitral valve therapy still surgical?

2015

Mitral regurgitation (MR) is the second most common valvular heart disease after aortic valve stenosis. With increased understanding of the heterogenic pathophysiology of MR, cardiac surgeons have developed various techniques that increase the likelihood of successful mitral valve repair (MVR). Nowadays, a rate of repair >90% may be reached in some mitral valve reference centres. In recent years, the introduction of transcatheter mitral valve intervention techniques has opened up new frontiers in mitral therapy, specifically in patients at high risk for standard surgery. Current percutaneous technologies for MVR have been developed on the basis of some of the surgical principles. Based on c…

medicine.medical_specialtyMitral valve repairMitral regurgitationPercutaneousbusiness.industryClinical outcomemedicine.medical_treatmentStandard treatmentMitraClipNew devicevalvular heart diseasemedicine.diseasemedicine.anatomical_structureAortic valve stenosisInternal medicineMitral valvecardiovascular systemmedicineCardiologyTranscatheter mitral valve therapybusinessCardiology and Cardiovascular MedicineMitral valve repairLong-term repair result
researchProduct

New approaches in the treatment of Adamantiades-Behçet's disease.

2005

Purpose of review To update clinicians on the recent advances in the treatment of Adamantiades-Behcet's disease. Recent findings Interferon-α-2a and infliximab have proved able to induce prompt remission in the vast majority of Adamantiades-Behcet's patients with DMARD-resistant uveoretinitis. Efficacy of interferon-α-2a has also been reported for mucocutaneous lesions, arthritis, and (more anecdotally) for neuro-Behcet, while results from small case series suggest that infliximab is beneficial for mucocutaneous lesions and (more anecdotally) for arthritis and gastro-intestinal manifestations. Two cases of neuro-Behcet treated with infliximab showed a complete resolution. Finally, in a rand…

medicine.medical_specialtyMucocutaneous zoneArthritisBehcet's diseaseDiseaseInterferon alpha-2Receptors Tumor Necrosis Factorlaw.inventionEtanerceptEtanerceptRheumatologyRandomized controlled triallawAntibodies Monoclonal; Behcet Syndrome; Chaperonin 60; Humans; Immunoglobulin G; Immunologic Factors; Interferon-alpha; Receptors Tumor Necrosis Factor; Recombinant ProteinsmedicineHumansImmunologic FactorsIFN-α2abusiness.industryBehcet SyndromeAntibodies MonoclonalInterferon-alphaChaperonin 60medicine.diseaseDermatologyeye diseasesInfliximabAdamantiades-Behçet's diseaseInfliximabRecombinant Proteinsstomatognathic diseasesImmunoglobulin GImmunologyTumour necrosis factorbusinessTolerizationUveitismedicine.drugCurrent opinion in rheumatology
researchProduct

Clinical and histopathological study of the oral multifocal melanoacanthoma : a case report

2019

Melanoacanthoma is a blackened mucocutaneous lesion, mainly affecting individuals with dark skin and exhibiting rapid development. Differential diagnosis includes nevus, amalgam tattoo and melanoma. This article reports a case of a 53-year-old white woman, who exhibited multiple blackened lesions on the gingiva and upper lip. After incisional biopsy, the presence of numerous melanin-containing dendritic cells distributed throughout the epithelial thickness, which were S-100 (+), were observed microscopically. Final diagnosis was multifocal oral melanoacanthoma. Follow-up for 28 months has shown appearing of more lesions in gingiva and upper lip. Therefore, the importance of differential dia…

medicine.medical_specialtyMucocutaneous zoneCase Report030209 endocrinology & metabolismLesion03 medical and health sciences0302 clinical medicinestomatognathic systemmedicineNevusOral mucosaGeneral DentistryOral Medicine and Pathologybusiness.industryMelanomaAmalgam tattoo030206 dentistry:CIENCIAS MÉDICAS [UNESCO]medicine.diseaseDermatologyMelanoacanthomastomatognathic diseasesmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASmedicine.symptomDifferential diagnosisbusiness
researchProduct

Gender-related disparities in the treatment and outcomes in patients with non-ST-segment elevation myocardial infarction: results from the Polish Reg…

2017

Introduction: Gender-related differences in the treatment of patients with non-ST elevation myocardial infarction (NSTEMI) have been reported in many previous studies despite the fact that an equal approach is recommended in all current guidelines. The aim of the study was to investigate whether gender-related discrepancies in the management of NSTEMI patients have changed. Material and methods: Between 2012 and 2014 a total of 66,667 patients (38.3% of whom were women) with the final diagnosis of NSTEMI were included into the retrospective analysis of the Polish Registry of Acute Coronary Syndromes (PL-ACS). Differences in clinical profile, treatment, and outcomes were analysed. Results: W…

medicine.medical_specialtyMultivariate analysismedicine.medical_treatmentAge adjustmentPopulationelderly03 medical and health sciences0302 clinical medicineClinical ResearchInternal medicinemedicineST segment030212 general & internal medicineMyocardial infarctioneducationeducation.field_of_studybusiness.industryMortality rateinvasive treatmentPercutaneous coronary interventionGeneral Medicinemedicine.diseaseGender relatedmortalitynon-ST elevation myocardial infarctionwomenbusinessArchives of Medical Science
researchProduct

Annual Trends in Total Ischemic Time and One-Year Fatalities: The Paradox of STEMI Network Performance Assessment

2019

This study is aimed at assessing trends and relations between total ischemic time, the major quality measure of systemic delay, and case-fatality at the population or patient level in response to growing cardiovascular risk and a constant need to shorten the time to treatment in ST-segment elevation myocardial infarction (STEMI). Data from a prospective nationwide registry of STEMI patients admitted between 2006 and 2013 who were treated with primary percutaneous coronary intervention (PCI) were analyzed. Total ischemic time was calculated as the time from the onset of symptoms to primary PCI and was determined as individual and annual. The primary end-point was one-year, all-cause case-fat…

medicine.medical_specialtyMultivariate analysismedicine.medical_treatmentPopulationlcsh:MedicineIschemic time030204 cardiovascular system & hematologyArticleSTEMI03 medical and health sciencestotal ischemic time0302 clinical medicineInternal medicineCase fatality ratemedicinecase-fatality030212 general & internal medicineMyocardial infarctioncardiovascular diseasesRisk factoreducationeducation.field_of_studybusiness.industrylcsh:RPercutaneous coronary interventionGeneral Medicinemedicine.diseaseConventional PCInetworkCardiologybusinessJournal of Clinical Medicine
researchProduct